Neuro-ophthalmologic manifestations of sarcoidosis

被引：15

作者：

Stern B.J. ^{[1
]}

Corbett J. ^{[1
]}

机构：

[1] Department of Neurology, University of Maryland, Baltimore, MD 21201

来源：

Current Treatment Options in Neurology | 2007年 / 9卷 / 1期

关键词：

Etanercept; Sarcoidosis; Uveitis; Thalidomide; Adalimumab;

D O I：

10.1007/s11940-007-0032-3

中图分类号：

学科分类号：

摘要：

The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved. Copyright © 2007 by Current Science Inc.

引用

页码：63 / 71

页数：8

共 22 条

[1]

Gullapalli D., Phillips L.H., II: Neurological manifestations of sarcoidosis, Neurol Clin, 20, pp. 59-83, (2002)

[2]

Krumholz A., Stern B.J., Neurological manifestations of sarcoidosis, Handbook of Clinical Neurology, Systemic Diseases, Part III, pp. 463-523, (1998)

[3]

Baughman R.P., Teirstein A.S., Judson M.A., Et al., Clinical characteristics of patients in a case control study of sarcoidosis. A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group, Am J Resp Crit Care Med, 164, pp. 1885-1889, (2001)

[4]

Rybicki B.A., Iannuzzi M.C., Frederick M.M., Et al., Familial aggregation of sarcoidosis: A Case-Control Etiologic Study of Sarcoidosis (ACCESS), Am J Resp Crit Care Med, 164, pp. 2085-2091, (2001)

[5]

Gal A.A., Koss M.N., The pathology of sarcoidosis, Curr Opin Pulm Med, 8, pp. 445-451, (2002)

[6]

Nowak D.A., Widenka D.C., Neurosarcoidosis: A review of its intracranial manifestation, J Neurol, 248, pp. 363-372, (2001)

[7]

Heuser K., Kerty E., Neuroophthalmological findings in sarcoidosis, Acta Ophthalmol Scand, 82, pp. 723-729, (2004)

[8]

Constantino T., Digre K.B., Zimmerman P., Neuro-ophthalmic complications of sarcoidosis, Semin Neurol, 20, pp. 123-135, (2000)

[9]

Zajicek J.P., Scolding N.J., Foster O., Et al., Central nervous system sarcoidosis: Diagnosis and management, Q J Med, 92, pp. 103-117, (1999)

[10]

Johns C.J., Michele T.M., The clinical management of sarcoidosis: A 50-year experience at the Johns Hopkins Hospital, Medicine, 78, pp. 65-111, (1999)

← 1 2 3 →